Biotech business with an excellent safety record of more than 2500 clinical treatments. Company designs, manufactures, and markets affinity blood filtration products. A new and highly innovative hemofiltration device that uses patented and proprietary biomimetic technology to quickly remove bacteria, fungi, bacterial toxins, viruses, proinflammatory cytokines, and sepsis mediators from a patient who is afflicted with bloodstream infection.
Investment Appeal
Millions of patients affected globally sepsis market north of 30 million cases each year.
Other applications of this technology may be used as a countermeasure for bioweapons attack (COVID), PDAC cancer, to prevent the side effects of the use of ECMO and cardiopulmonary bypass in diagnostics, blood banking, and bioprocessing.
Just 10x trailing net income could value the company up to $40 Billion by the end of 2028.
Growth Opportunity
Strong Management
Gross Profit Margins >85%
